Physician profile
James Michael Leonardo
NPI 1285699017
$4,618.84
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $827 · 2021: $1,983 · 2022: $1,035.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $758.39 | 2019-2022 | |
| Pfizer INC. | $447.87 | 2019-2022 | |
| Amgen INC. | $421.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $402.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $272.75 | 2019-2022 | |
| Celgene Corporation | $203.41 | 2019-2022 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $156.77 | 2021-2022 | |
| Genzyme Corporation | $144.94 | 2020-2022 | |
| Puma Biotechnology, INC. | $143.30 | 2019-2021 | |
| Lilly USA, LLC | $138.09 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $126.94 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.95 | 2019-2022 | |
| Dova Pharmaceuticals | $95.83 | 2020-2021 | |
| Eisai INC. | $94.50 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $92.84 | 2020-2022 | |
| Exelixis INC. | $82.38 | 2019-2022 | |
| Genentech USA, INC. | $78.49 | 2019-2022 | |
| Daiichi Sankyo INC. | $70.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.64 | 2020-2022 | |
| Janssen Biotech, INC. | $60.95 | 2020-2022 | |
| Beigene USA, INC. | $53.44 | 2020-2022 | |
| Incyte Corporation | $41.40 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.07 | 2021-2022 | |
| Abbvie INC. | $37.75 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $37.27 | 2021 | |
| Emd Serono, INC. | $37.27 | 2021-2022 | |
| Clovis Oncology, INC. | $28.99 | 2020-2021 | |
| Blueprint Medicines Corporation | $24.42 | 2021 | |
| Glaxosmithkline, LLC. | $23.93 | 2021 | |
| Adaptive Biotechnologies Corporation | $22.98 | 2022 | |
| Rigel Pharmaceuticals, INC. | $19.64 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.47 | 2022 | |
| Astellas Pharma US INC | $17.38 | 2022 | |
| Karyopharm Therapeutics INC. | $15.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.30 | 2020 | |
| Epizyme, INC. | $14.82 | 2021 | |
| Taiho Oncology, INC. | $13.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Leonardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.